表皮生长因子受体酪氨酸激酶抑制剂联合化疗治疗肺癌的研究进展

Advances in epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy for lung cancer treatment

表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（EGFR—TKI）对EGFR突变肺癌患者表现出很好的疗效，对于EGFR野生型肺癌患者化疗药物是首选，EGFR-TKI和化疗药物联合在基础研究方面表现出良好的协同作用，而在临床研究方面与其两药联合的时序有关。

Epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） show good efficacy for the lung cancer patients with EGFR mutations. Chemotherapy drugs are the first choices for the lung cancer patients with EGFR wild-type. In basic research, EGFR-TKIs combination with chemotherapy drugs show good synergy. But in clinical research, the timing of EGFR-TKIs combination with chemotherapy drugs is related to the efficacy.